转录激活因子2和切除修复交叉互补基因1与卵巢癌顺铂耐药的关系

Relationships between the expressions of ATF-2,ERCC1 and cisplatin resistance in ovarian carcinoma

目的:探讨转录激活因子-2(ATF-2)、切除修复交叉互补基因1(ERCC1)表达在卵巢上皮性癌顺铂化疗耐药中的意义。方法:应用SP法检测56例石蜡包埋卵巢癌标本及RT-PCR方法检测34例卵巢癌新鲜组织ATF-2、ERCC1蛋白及mRNA的表达,分析其与顺铂耐药的关系以及二者的相关性。结果:ATF-2表达与患者年龄、组织学类型及有无腹水无关,不同手术分期其表达差异有统计学意义(P<0.05)。ERCC1表达与卵巢上皮性癌患者年龄、手术分期、病理组织学类型及有无腹水无关(P>0.05)。顺铂化疗耐药组ATF-2、ERCC1蛋白的阳性表达率分别为69.23%、73.08%,高于化疗敏感组33.33%、46.67%,组间差异有统计学意义(P<0.05)。RT-PCR结果显示34例卵巢上皮性癌新鲜组织ATF-2/β-actin mRNA、ERCC1/β-actin分别波动于0.181～2.276、0.294～3.060,化疗耐药者ATF-2 mRNA、ERCC1 mRNA相对表达量分别为1.132±0.645、1.565±0.714,亦高于敏感组0.651±0.461、0.594±0.268,差异有统计学意义(P<0.05)。结论:ATF-2、ERCC1表达与卵巢上皮性癌顺铂耐药有关,可能成为预测卵巢癌顺铂敏感性指标。

Objective： To investigate the significance of the expressions of ATF-2,ERCC1 in cisplatin resistance of ovarian epithelial carcinoma.Methods： The expressions of ATF-2,ERCC1 proteins in 56 ovarian cancer samples were examined by Streptavidin-peroxidase complex technique and the semi-quantitative reverse transcription polymerase chain reaction（RT-PCR）method were applied to assess the mRNA levels of ATF-2,ERCC1 genes in 34 ovarian carcinoma fresh tissues,the relationships were analyzed between the expressions of ATF-2,ERCC1 and cisplatin resistance.Results： The expressions of ERCC1 did not show any association with patient age,FIGO stage,pathologic type and ascitic fluid,the expressions of ATF-2 were related to FIGO stage.The positive rates of ATF-2,ERCC1 proteins in chemoresistant group were 69.23%,73.08% respectively,those of chemosensitive one were 33.33%,46.67%,with significant difference between the two groups（P0.05）.The RT-PCR results showed up the range of ATF-2/β-actin mRNA levels were from 0.181 to 2.276,ERCC1/β-actin mRNA levels were from 0.294 to 3.060,the mean of ATF-2 mRNA,ERCC1 mRNA levels in chemoresistant patients were1.132±0.645,1.565±0.714 respectively,higher than those of chemosensitive patients 0.651±0.461,0.594±0.268（P0.05）.Conclusion： The expressions of ATF-2,ERCC1 were related to cisplatin resistance in ovarian epithelial carcinoma,which may be valuable in predicting cisplatin response.